CU, N., MD, L., J, D., S, K., L, E., GJ, V., . . . AP, K. (2021). Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia. Blood, 137(8), 1117. https://doi.org/10.1182/blood.2020008608
Chicago Style (17th ed.) CitationCU, Niemann, et al. "Venetoclax and Ibrutinib for Patients with Relapsed/refractory Chronic Lymphocytic Leukemia." Blood 137, no. 8 (2021): 1117. https://doi.org/10.1182/blood.2020008608.
MLA (9th ed.) CitationCU, Niemann, et al. "Venetoclax and Ibrutinib for Patients with Relapsed/refractory Chronic Lymphocytic Leukemia." Blood, vol. 137, no. 8, 2021, p. 1117, https://doi.org/10.1182/blood.2020008608.
Warning: These citations may not always be 100% accurate.
